Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Mountain View, California
- Most recent report
- 8-K, filed Aug 27, 2026
- Incorporated
- Delaware
- Filings on record
- 192 filings
- On EDGAR
- CIK 1999480
- Fiscal year ends
- December
- Filer status
- Emerging growth company
Financials 8 of 11
News 8 of 30
Prospectuses and Registrations 8 of 11
- 424B5 Prospectus supplement for an offering Jul 14, 2026
- S-3 Shelf registration statement Apr 10, 2026
- S-8 Registration statement for an employee plan Mar 16, 2026
- S-3 Shelf registration statement Nov 28, 2025
- S-8 Registration statement for an employee plan Mar 20, 2025
- S-3 Shelf registration statement Feb 3, 2025
- S-8 Registration statement for an employee plan Feb 6, 2024
- 424B4 Final prospectus for an offering Feb 5, 2024
Proxies 5
Ownership 8 of 102
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Jul 27, 2026
- SCHEDULE 13G Large holder reported a passive stake Jul 20, 2026
- 4 Insider reported a trade May 29, 2026
- 3 Insider reported their initial holding May 29, 2026
- 4 Insider reported a trade May 15, 2026
Other 8 of 33
- EFFECT Notice that a registration became effective Apr 20, 2026
- CORRESP Reply to SEC staff Apr 17, 2026
- UPLOAD Comment letter from SEC staff Apr 16, 2026
- ARS Annual report sent to shareholders Mar 26, 2026
- EFFECT Notice that a registration became effective Dec 10, 2025
- CORRESP Reply to SEC staff Dec 8, 2025
- D Oct 27, 2025
- ARS Annual report sent to shareholders Apr 1, 2025
Everything here comes from Alto Neuroscience, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.